Roger Gomis (IRB Barcelona)
A new company spun off from the Institute of Research in Biomedicine in Barcelona, Spain (IRB Barcelona), will develop a diagnostic kit and treatments for breast cancer metastasis. Supragen is founded and commercializes research by Roger Gomis (pictured right), group leader of IRB Barcelona’s Growth Control and Cancer Metastasis lab.
The lab investigates growth factors, signalling pathways, and gene expression programs that control normal cell proliferation and cancer cell metastasis. From this research, Gomis and his lab colleagues have identified a gene with the capacity to predict the risk of metastasis of breast cancer to the bone.
Supragen will develop a tools to diagnose breast cancer patients with a high risk of suffering metastasis to the bone, considered the most common kind of metastasis in this kind of cancer. These diagnostics are expected to allow physicians to design and modify current treatments to adapt to the risk of each patient. The company also plans to develop new therapeutic molecules that inhibit the gene, since its activity is required for metastasis to bone.
Gomis’s company is the second biotechnology enterprise to emerge from the IRB Barcelona this year, and the third to spin off from the institute since 2005. Iproteos was founded in June 2011 by Ernest Giralt and Teresa Tarragó. Omnia Molecular, was created in in 2005 by Lluís Ribas de Pouplana.
Read more: FDA Approves Genetic Test for Breast Cancer Treatment
* * *
RSS - Posts
You must be logged in to post a comment.